Abstract
Laryngeal carcinoma is one of the most common malignant tumors of the head, neck, and respiratory tract. The aim of the present study is to explore the biological function of SRY-related HMG-box 18 (SOX18) in laryngeal carcinoma cells and study the molecular mechanism involved. Initial findings indicate that the expression of SOX18 was increased in laryngeal carcinoma cell lines and tissues. The effect of SOX18 on laryngeal carcinoma cell proliferation, cell cycle, apoptosis, invasion, and migration was also identified. The results indicated that down-regulation of SOX18 significantly inhibited cell proliferation, migration, and invasion, and induced cell-cycle arrest in G0/G1 phase and apoptosis of laryngeal carcinoma cells. However, overexpression of SOX18 promoted cell proliferation, invasion, and migration, and inhibited cell apoptosis. The expression of cyclin D1, active-caspase-3, N-cadherin, MTA1, MMP-2, and MMP-7 was also regulated by the overexpression of siSOX18 or SOX18. In addition, it was found that SOX18 could also accelerate the phosphorylation of JAK2/STAT3 signaling in laryngeal carcinoma cells. Furthermore, our study indicated that SOX18 could stimulate cell proliferation, migration, and invasion of laryngeal carcinoma cells via regulation of JAK2/STAT3 signaling, which could provide a new strategy for laryngeal carcinoma diagnosis and molecular therapies.
Highlights
Laryngeal carcinoma is one of the most common malignant tumors among people with a history of head and neck tumors
The results showed that SRY-related HMG-box 18 (SOX18) might act as an oncogene in the occurrence and progression of laryngeal carcinoma
Laryngeal cancer is the most common malignant tumor in the department of otorhinolaryngology and ranked second among the head and neck primary malignant tumors, which are of epithelial origin
Summary
Laryngeal carcinoma is one of the most common malignant tumors among people with a history of head and neck tumors. The overall incidence of laryngeal cancer has remarkably increased and has become the second most common cancer of respiratory system [1,2]. Advances in medical science and technology has improved the treatment of laryngeal cancer, including surgery, chemotherapy, radiotherapy, and targeted drugs, it could not improve the overall survival rate of patients with laryngeal cancer [3,4]. Improving the early diagnosis rate of laryngeal carcinoma, early prediction of recurrence and effective intervention measures are the key to improve the curative effect of laryngeal carcinoma [5,6]. Advances in molecular medicine has helped in finding the specific therapeutic target for treatment, improving the curative effect of laryngeal cancer [7,8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
